Curaleaf Sets December 1 Tender Deadline, Escalates Hostile Bid for Aurora
CURLF sits 88% above its 52-week low of $5.4 on light trading volume (0.3× avg).
Summary
Curaleaf published a shareholder brochure setting a December 1, 2026 tender deadline and revealing new financial deterioration data about Aurora, including US$398M in dilutive equity issuances and a 78% decline in adjusted EBITDA.
Key Events · M&A and Partnerships · CURLF
-
Tender Deadline Set for December 1, 2026
A concrete deadline for the hostile takeover bid is now in place: Aurora shareholders must tender their shares before December 1, 2026, as explicitly stated in Curaleaf's brochure.
-
Aurora Raised US$398M Through Dilutive Equity
Aurora management raised US$398M through dilutive equity issuances, a move Curaleaf argues has made Aurora shares less valuable.
-
Aurora Financial Deterioration Detailed
Over the last four quarters, Aurora's net revenue declined 14% and adjusted EBITDA declined 78%, with operating cash flow negative US$18M (LTM, adjusted for lease principal payments).
-
Auditor Concerns Over Inventory Controls
Adding a governance concern to the financial deterioration narrative, Curaleaf claims Aurora's own auditors question management's inventory controls.
Analysis · CURLF · Life Sciences
A December 1, 2026 tender deadline and fresh financial deterioration data about Aurora Cannabis mark a significant escalation in Curaleaf's hostile takeover campaign. The shareholder brochure reveals that Aurora raised US$398M through dilutive equity issuances, burned US$18M in operating cash flow over the last twelve months, and saw net revenue decline 14% and adjusted EBITDA decline 78% over the last four quarters. Curaleaf also claims Aurora's own auditors question management's inventory controls. These new material facts strengthen the case that Aurora shareholders should accept the US$4.00 per share offer, a 45% premium to the 30-day VWAP on August 10, 2026. The tender deadline creates urgency for Aurora shareholders to act.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.